Could SGLT2 Inhibitors Directly Influence the Biology of Aging?

SGLT2 inhibitors cause glucose to be lost through the urine, changing how the body manages its energy supply.

This can increase reliance on fatty acids and ketone bodies as alternative energy sources. The authors describe aspects of this metabolic adaptation as resembling changes seen during calorie restriction and ketogenic conditions.

This is relevant because nutrient sensing and energy metabolism are closely connected with the biology of aging.

It provides a plausible mechanism for effects extending beyond glucose control, although it does not mean that SGLT2 inhibitors reproduce the longevity effects of calorie restriction.

Persistent low-grade inflammation is associated with aging and many age-related diseases.

The review describes evidence that SGLT2 inhibitors can attenuate systemic inflammation, potentially linking their metabolic effects with cardiovascular, kidney and aging-related pathways.

Reducing excessive inflammation may therefore be one mechanism contributing to their broader health effects. Whether this slows biological aging in humans remains unknown.

Mitochondrial dysfunction is one of the biological changes associated with aging.

Evidence reviewed by the authors suggests that SGLT2 inhibition may improve aspects of mitochondrial function and cellular resilience.

Together with changes in energy metabolism and inflammation, this suggests that SGLT2 inhibitors may influence several interconnected processes involved in aging rather than a single biological pathway.

One of the most interesting areas discussed in the review is cellular senescence.

Senescent cells are damaged or stressed cells that have stopped dividing but remain metabolically active. They can accumulate with age and release inflammatory and tissue-disrupting molecules known collectively as the senescence-associated secretory phenotype, or SASP.

Experimental evidence reviewed by the authors suggests that SGLT2 inhibitors may reduce senescent-cell burden and modify SASP activity.

The authors also discuss possible senolytic properties — the ability to selectively eliminate some senescent cells.

This creates an intriguing connection between SGLT2 inhibition and a major mechanism of aging. However, senolytic activity remains an emerging experimental hypothesis rather than an established clinical effect in humans.

The experimental evidence extends beyond individual molecular pathways.

Animal studies reviewed by the authors have reported that SGLT2 inhibition can extend lifespan and reduce age-related functional decline.

This is important because it suggests that molecular and cellular effects can translate into outcomes relevant to aging of the whole organism.

These findings strengthen the rationale for studying SGLT2 inhibitors as potential geroprotective drugs.

However, the evidence is preclinical. Longer lifespan in animal models does not establish longer lifespan in humans.